Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00646958
Recruitment Status : Completed
First Posted : March 31, 2008
Results First Posted : June 26, 2009
Last Update Posted : March 27, 2014
Information provided by (Responsible Party):
Melinta Therapeutics, Inc.

Brief Summary:
The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections

Condition or disease Intervention/treatment Phase
Infectious Skin Diseases Bacterial Skin Diseases Staphylococcal Skin Infections Streptococcal Infections Abscess Drug: Radezolid Drug: Linezolid Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection
Study Start Date : December 2007
Actual Primary Completion Date : April 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Linezolid

Arm Intervention/treatment
Experimental: 1
Radezolid 450 mg PO QD
Drug: Radezolid
450mg PO QD
Other Name: RX-1741

Experimental: 2
Radezolid 450 mg PO BID
Drug: Radezolid
450mg PO BID
Other Name: RX-1741

Active Comparator: 3
Linezolid 600 mg PO BID
Drug: Linezolid
600mg PO BID
Other Name: Zyvox

Primary Outcome Measures :
  1. Number of Participants With a Clinical Response of Cure [ Time Frame: Test of Cure (TOC), day 10-20 ]
    To qualify as a Cure, participants were required to fulfill the following criteria: all systemic signs and symptoms of uSSSI present at screening were improved or resolved; no further antibiotic therapy was necessary for treatment of uSSSI; and there was no worsening or appearance of new signs and symptoms of uSSSI.

Secondary Outcome Measures :
  1. Number of Patients With Per-Patient Microbiologic Response of Eradicated [ Time Frame: Test of Cure (TOC), day 10-20 ]
    The microbiological response at the patient level was considered Eradicated (documented or presumed)if no pathogens were present in repeat cultures taken from the original site of infection or a clinical response of cure precluded the ability to obtain a culturable specimen.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients with uSSSI
  • Adult (men and women) ≥18 years
  • Females must be post-menopausal for at least 1 year or surgically sterile
  • Sexually active males must use a barrier method of birth control during and for 30 days after the study
  • Acceptable clinical diagnoses of uSSSI include, but are not limited to: Simple abscess, Impetiginous lesions, Folliculitis, Furunculosis, Carbuncles, Cellulitis
  • The infection is accompanied by 2 or more of the following local signs and symptoms: Pain/tenderness, Swelling, Erythema, Localized warmth, Purulent drainage/discharge, Induration, Regional lymph node swelling or tenderness, Extension of redness
  • A sample for microbiologic culture must be obtained from the primary infection site at the screening visit
  • The patient must require and be a suitable candidate for oral antibiotic therapy in the opinion of the Investigator and be able to swallow tablets or capsules intact
  • A written, voluntarily signed informed consent must be obtained from the patient prior to the initiation of any study-related procedures

Exclusion Criteria:

  • Cellulitis (area greater than 10cm2), chronic or recurrent furunculosis, postoperative wound infection, leg ulcer, decubitus ulcer(s), erysipelas, progressive lymphangitis, acute paronychia or a deep tissue abscess such as pilonidal or breast abscess. Also excluded are skin infections resulting from animal bites
  • Patients with a complicated skin and skin structure infection as judged by the Investigator
  • Infections that can be treated by surgical incision alone according to the judgment of the Investigator
  • Treatment with the following anti-infective agents prior to study drug administration: systemic antibiotic within 7 days; azithromycin within 14 days; a long-acting injectable antibiotic within 30 days
  • Any infection which requires the use of a concomitant antimicrobial agent, in addition to study drug
  • Concomitant topical therapy at the infection site for the period within 48 hours prior to study drug administration through TOC
  • A chronic or underlying skin condition at the site of infection or infections involving prosthetic materials
  • A wound secondary to burn injury or acne vulgaris
  • Any infection site that requires: intraoperative surgical debridement; excision of infected area
  • Documented or suspected bacteremia
  • Fungal infection involving the nail bed or scalp at the primary uSSSI site
  • Significant peripheral vascular disease
  • An abscess at an anatomical location where the incidence of anaerobic pathogen involvement is increased
  • Patient receiving a daily dose of > 15 mg of systemic prednisone or equivalent, for > 10 days within the period starting 14 days prior to study drug administration or anticipated through TOC
  • Patient with known human immunodeficiency virus (HIV) infection.
  • Medical history of hypersensitivity or allergic reaction to linezolid according to the judgment of the Investigator
  • Patients receiving serotonergic agents, selective serotonin reuptake inhibitors (SSRIs), or monoamine oxidase inhibitors (MAOIs)
  • Patients who have severe liver disease
  • History of pheochromocytoma, untreated hyperthyroidism, untreated or uncontrolled hypertension, carcinoid syndrome
  • Evidence of uncontrolled, clinically significant (according to the judgment of the Investigator) cardiovascular, pulmonary, metabolic, gastrointestinal, neurological, or endocrine disease; malignancy or psychiatric disorder
  • Current evidence of deep vein thrombosis or superficial thrombophlebitis
  • Experienced a recent clinically significant coagulopathy
  • Evidence of clinically significant immunosuppression
  • Patient who previously enrolled in this study
  • Patient who has previously enrolled in any other clinical trial within 4 weeks of enrollment through TOC. Treatment with an investigational drug within 4 weeks prior to study drug administration
  • Patient residing in a chronic care facility
  • Any underlying condition or disease state that would interfere with the completion of the study procedures and evaluation of the absorption of study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00646958

Show Show 19 study locations
Sponsors and Collaborators
Melinta Therapeutics, Inc.
Layout table for investigator information
Study Director: Scott Hopkins, MD Melinta Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Melinta Therapeutics, Inc. Identifier: NCT00646958    
Other Study ID Numbers: RX-1741-202
First Posted: March 31, 2008    Key Record Dates
Results First Posted: June 26, 2009
Last Update Posted: March 27, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Skin Diseases, Infectious
Streptococcal Infections
Staphylococcal Skin Infections
Skin Diseases, Bacterial
Skin Diseases
Disease Attributes
Pathologic Processes
Connective Tissue Diseases
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Staphylococcal Infections
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action